21 CFR Part 212 CGMP for Positron Emission Tomography Drugs


Click on the titles below for complete guidelines

Subpart A—General Provisions

212.1   What are the meanings of the technical terms used in these regulations?

212.2   What is current good manufacturing practice for PET drugs?

212.5   To what drugs do the regulations in this part apply?


Subpart B—Personnel and Resources

212.10   What personnel and resources must I have?


Subpart C—Quality Assurance

212.20   What activities must I perform to ensure drug quality?


Subpart D—Facilities and Equipment

212.30   What requirements must my facilities and equipment meet?


Subpart E—Control of Components, Containers, and Closures

212.40   How must I control the components I use to produce PET drugs and the containers and closures I package them in?


Subpart F—Production and Process Controls

212.50   What production and process controls must I have?


Subpart G—Laboratory Controls

212.60   What requirements apply to the laboratories where I test components, in-process materials, and finished PET drug products?

212.61   What must I do to ensure the stability of my PET drug products through expiry?


Subpart H—Finished Drug Product Controls and Acceptance

212.70   What controls and acceptance criteria must I have for my finished PET drug products?

212.71   What actions must I take if a batch of PET drug product does not conform to specifications?


Subpart I—Packaging and Labeling

212.80   What are the requirements associated with labeling and packaging PET drug products?


Subpart J—Distribution

212.90   What actions must I take to control the distribution of PET drug products?


Subpart K—Complaint Handling

212.100   What do I do if I receive a complaint about a PET drug product produced at my facility?


Subpart L—Records

212.110   How must I maintain records of my production of PET drugs?

21 CFR Part 212 CGMP for Positron Emission Tomography Drugs

Post a Comment